Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Mark Osterman, MD, MSCE

Mark Osterman, MD, MSCE Physician

Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Languages spoken:

  • Croatian

Dr. Osterman is employed by Penn Medicine.

About Dr. Mark Osterman

Recognized by America's Top Doctors for 2017

Recognized in Philadelphia magazine's May 2018 Top Docs issue

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Gastroenterology

Programs & Centers:

Board Certification:

  • Gastroenterology, 2005

Clinical Expertise:

  • Anal Cancer
  • Bile Duct Cancer (Cholangiocarcinoma)
  • Colon Cancer
  • Crohn's Disease
  • Esophageal Cancer
  • Gallbladder Cancer
  • Gastrointestinal Carcinoid Tumor
  • Inflammatory Bowel Disease (IBD)
  • Liver Cancer
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • Rectal Cancer
  • Small Intestine Cancer
  • Stomach Cancer (Gastric Cancer)

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Harvard Medical School
Residency: Brigham and Women's Hospital
Fellowship: Hospital of the University of Pennsylvania

Memberships

Abbvie, International American Gastroenterological Association, National American Gastroenterological Association, National Crohn's and Colitis Foundation of America, National Elan Pharmaceuticals, National Janssen Pharmaceuticals, International Lycera, International Pfizer, National Takeda Pharmaceuticals, International UCB Worldwide, National

Hospital Affiliation

Dr. Osterman is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Medicine Radnor: Has privileges to perform procedures.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Papamichael K, Vajravelu R, Cheifetz AS, Osterman MT: Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease Digestive Diseases and Sciences : 2018.

Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease Gastroenterology : 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 15 : 1197-9,2017.

Osterman MT, Foley C, Matthias I: Clozapine-induced acute gastrointestinal necrosis: a case report Journal of Medical Case Reports 11 : 270,2017.

Osterman MT: Ready or not, here they are: Anti-TNF biosimilars for IBD AGA Perspectives 13 : 12-3,2017.

Vajravelu R, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI: Indeterminate quantiFERON-TB gold increases likelihood of inflammatory bowel disease treatment delay and hospitalization Inflammatory Bowel Diseases 24 : 217-26,2017.

Lewis JD, Bewtra M, Scott FI, Brensinger CM, Reed SD, Roy JA, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Gilroy E, Sandler RS, Chen W, Curtis JR, Johnson R: Patient valued comparative effectiveness of tumor necrosis factor alpha inhibitors and corticosteroids for inflammatory bowel disease www.pcori.org : 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology : 2017.

Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab Clinical Gastroenterology and Hepatology 15 : 1580-8,2017.

Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies Gastroenterology : 2017.

View all publications

Academic Contact Info

Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 North 39th Street

Philadelphia, PA 19104
Phone: (215) 662-8900
Patient appointments: 800-789-7366 (PENN)

Related Links